Key result
Antidepressant therapy significantly reduced pain (SMD -1.26) and psychological symptoms compared to placebo in patients with functional chest pain, though it was associated with increased side effects.
Why the study?
Does antidepressant treatment reduce pain and psychological symptoms in patients with functional chest pain?
Meta-Analysis (n=319)
Does antidepressant treatment reduce pain and psychological symptoms in patients with functional chest pain?
In patients with functional chest pain, short-term antidepressant therapy significantly reduces pain and psychological symptoms but increases side effects without improving health-related quality of life.
Answers are grounded in this paper and cite their sources.
Antidepressants may be considered for functional chest pain when symptoms predominate; confirms efficacy on pain and mood but highlights side-effect and QoL trade-offs.
BACKGROUND: Recurrent Functional Chest pain (FCP) with normal coronary anatomy and no detectable gastroenterological and respiratory causes is a common problem that sometimes leads to excess use of medical care. OBJECTIVE: The purpose of this meta-analysis is to investigate the efficacy of antidepressant treatments for FCP. SETTINGS: MEDLINE, PsycINFO, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched up to July 2011. Randomized controlled trials (RCTs) that tested any type of antidepressants for FCP with normal coronary anatomy were analyzed. Diagnoses included non-specific chest pain, noncardiac chest pain, atypical chest pain, syndrome X, or chest pain with normal coronary anatomy. METHODS: Two authors independently extracted data. Effects were summarized using standardized mean differences (SMDs), weighed mean differences (WMD), or odds ratio (OR) by suitable effects model. RESULTS: Seven RCTs (median duration, 5 weeks; range, 3 - 16 weeks) involving 319 participants were included. There was strong evidence for an association of antidepressants with reduction in pain (SMD -1.26; 95% confidence interval [CI], -2.34 to -0.19) and psychological symptoms (SMD -0.87; 95% CI, -1.67 to - 0.08) as well as increased side effects (OR 0.34; 95% CI, 0.15 to 0.78). Current analysis did not support the association of antidepressants with improved health related quality of life (WMD 2.00; 95% CI, - 2.54 to - 6.65). LIMITATIONS: Demographics, co-morbidities of study participants and the amount of co-medication were not reported, these possible sources of heterogeneity could not be examined. CONCLUSIONS: Antidepressant medications are associated with improvements in pain and psychological symptoms. The effects of factors including psychiatric co-morbidity, gender, age, ethnic group, and treating period on the outcomes should be checked further.
No takes yet. Share an insight, caveat, or question.
A 2012 study conducted a meta-analysis in Functional Chest Pain (n=319). Antidepressants vs. Placebo was evaluated on Reduction in pain (SMD -1.26, 95% CI -2.34 to -0.19, p=0.02). Antidepressant therapy significantly reduced pain (SMD -1.26) and psychological symptoms compared to placebo in patients with functional chest pain, though it was associated with increased side effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: